drugset / Trial / NCT01951027
Phase I Study GX-G3 in Healthy Subjects
RandomizedParallel-groupDouble-blindScreening
Summary
pharmacokinetics/pharmacodynamics of GX-G3 after single subcutaneous administration in healthy male subjects.
Timeline
- Start
- 2013-09
- Primary completion
- 2014-07
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GX-G3 | Unknown | 12.5 ug/kg | Subcutaneous |
| Subject | GX-G3 | Unknown | 25 ug/kg | Subcutaneous |
| Subject | GX-G3 | Unknown | 50 ug/kg | Subcutaneous |
| Subject | GX-G3 | Unknown | 100 ug/kg | Subcutaneous |
Indications
No indication recorded.